- Home
- NRDS vs VIR Comparison
NRDS vs VIR Comparison
Compare NRDS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- VIR
- Stock Information
- Founded
- NRDS 2009
- VIR 2016
- Country
- NRDS United States
- VIR United States
- Employees
- NRDS N/A
- VIR N/A
- Industry
- NRDS EDP Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- VIR Health Care
- Exchange
- NRDS Nasdaq
- VIR Nasdaq
- Market Cap
- NRDS 810.0M
- VIR 706.4M
- IPO Year
- NRDS 2021
- VIR 2019
- Fundamental
- Price
- NRDS $10.59
- VIR $5.65
- Analyst Decision
- NRDS Buy
- VIR Strong Buy
- Analyst Count
- NRDS 6
- VIR 8
- Target Price
- NRDS $15.17
- VIR $30.25
- AVG Volume (30 Days)
- NRDS 417.1K
- VIR 1.2M
- Earning Date
- NRDS 07-30-2025
- VIR 07-31-2025
- Dividend Yield
- NRDS N/A
- VIR N/A
- EPS Growth
- NRDS N/A
- VIR N/A
- EPS
- NRDS 0.38
- VIR N/A
- Revenue
- NRDS $734,900,000.00
- VIR $20,861,000.00
- Revenue This Year
- NRDS $18.07
- VIR N/A
- Revenue Next Year
- NRDS $8.22
- VIR $0.62
- P/E Ratio
- NRDS $28.05
- VIR N/A
- Revenue Growth
- NRDS 24.20
- VIR N/A
- 52 Week Low
- NRDS $7.55
- VIR $4.32
- 52 Week High
- NRDS $16.45
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- NRDS 42.52
- VIR 57.21
- Support Level
- NRDS $11.07
- VIR $5.20
- Resistance Level
- NRDS $11.49
- VIR $6.23
- Average True Range (ATR)
- NRDS 0.32
- VIR 0.30
- MACD
- NRDS -0.04
- VIR 0.07
- Stochastic Oscillator
- NRDS 13.19
- VIR 56.06
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.